{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T06:03:58Z","timestamp":1748930638432},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T00:00:00Z","timestamp":1354665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s12253-012-9586-9","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T16:54:37Z","timestamp":1354640077000},"page":"1-10","source":"Crossref","is-referenced-by-count":8,"title":["Bone Homeostasis and Breast Cancer: Implications for Complex Therapy and the Maintenance of Bone Integrity"],"prefix":"10.1007","volume":"19","author":[{"given":"Orsolya","family":"Rusz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Kah\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,5]]},"reference":[{"key":"9586_CR1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","volume":"29","author":"CH Poznak Van","year":"2011","unstructured":"Van Poznak CH, Temin S, Yee GC et al (2011) American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221\u20131227","journal-title":"J Clin Oncol"},{"key":"9586_CR2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2010.10.007","volume":"37","author":"T Guise","year":"2010","unstructured":"Guise T (2010) Examining the metastatic niche: targeting the microenvironment. Semin Oncol 37:S2\u2013S14","journal-title":"Semin Oncol"},{"key":"9586_CR3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","volume":"328","author":"T Yoneda","year":"2005","unstructured":"Yoneda T, Hiraga T (2005) Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328:679\u2013687","journal-title":"Biochem Biophys Res Commun"},{"key":"9586_CR4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-007-9109-4","volume":"27","author":"MB Karen","year":"2008","unstructured":"Karen MB, Carol VG, Andrea MM (2008) The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 27:41\u201355","journal-title":"Cancer Metastasis Rev"},{"key":"9586_CR5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","volume":"49","author":"MJ Rogers","year":"2011","unstructured":"Rogers MJ, Crockett JC, Coxon FP, M\u00f6nkk\u00f6nen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49:34\u201341","journal-title":"Bone"},{"key":"9586_CR6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bone.2010.11.017","volume":"49","author":"P Cl\u00e9zardin","year":"2011","unstructured":"Cl\u00e9zardin P, Benza\u00efd I, Croucher PI (2011) Bisphosphonates in preclinical bone oncology. Bone 49:66\u201370","journal-title":"Bone"},{"key":"9586_CR7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00210-010-0596-4","volume":"383","author":"K Kimachi","year":"2011","unstructured":"Kimachi K, Kajiya H, Nakayama S et al (2011) Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis. N Schmied Arch Pharmacol 383:297\u2013308","journal-title":"N Schmied Arch Pharmacol"},{"key":"9586_CR8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","volume":"49","author":"C Serge","year":"2011","unstructured":"Serge C, Socrates P (2011) Pharmacology of bisphosphonates. Bone 49:42\u201349","journal-title":"Bone"},{"key":"9586_CR9","first-page":"189","volume":"7","author":"L Arboleya","year":"2011","unstructured":"Arboleya L, Alperi M, Alonso S (2011) Adverse effects of bisphosphonates. Rheumatol Clin 7:189\u2013197","journal-title":"Rheumatol Clin"},{"key":"9586_CR10","doi-asserted-by":"crossref","unstructured":"Ross JR, Saunders Y, Edmonds PM et al (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ http:\/\/www.bmj.com\/content\/327\/7413\/469 . Accessed 30 August 2003","DOI":"10.1136\/bmj.327.7413.469"},{"key":"9586_CR11","doi-asserted-by":"crossref","unstructured":"Wong MHF, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD003474.pub3\/full . Accessed 30 April 2011","DOI":"10.1002\/14651858.CD003474.pub3"},{"key":"9586_CR12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ncponc1323","volume":"6","author":"L Costa","year":"2009","unstructured":"Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bones metastases. Nat Clin Pract Oncol 6:163\u2013174","journal-title":"Nat Clin Pract Oncol"},{"key":"9586_CR13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-007-9583-y","volume":"108","author":"M Clemons","year":"2008","unstructured":"Clemons M, Dranitsaris G, Ooi W, Cole DEC (2008) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Canc Res Treat 108:79\u201385","journal-title":"Breast Canc Res Treat"},{"key":"9586_CR14","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","volume":"24","author":"MJ Clemons","year":"2006","unstructured":"Clemons MJ, Dranitsaris G, Ooi WS et al (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24:4895\u20134900","journal-title":"J Clin Oncol"},{"key":"9586_CR15","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT et al (2003) American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057","journal-title":"J Clin Oncol"},{"key":"9586_CR16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2174\/156800909789760375","volume":"9","author":"D Santini","year":"2009","unstructured":"Santini D, Fratto ME, Vincenzi B et al (2009) Denosumab: the era of targeted therapies in bone metastatic disease. Curr Canc Drug Targets 9:834\u2013842","journal-title":"Curr Canc Drug Targets"},{"key":"9586_CR17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677\u2013692","journal-title":"Bone"},{"key":"9586_CR18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.bone.2011.08.007","volume":"49","author":"Y Kumagai","year":"2011","unstructured":"Kumagai Y, Hasunuma T, Padhi D (2011) A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone 49:1101\u20131107","journal-title":"Bone"},{"key":"9586_CR19","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"9586_CR20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/02841860802001467","volume":"47","author":"NH Bjarnason","year":"2008","unstructured":"Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P (2008) Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol 47:747\u2013754","journal-title":"Acta Oncol"},{"key":"9586_CR21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78\u201384","journal-title":"J Clin Oncol"},{"key":"9586_CR22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS et al (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852\u2013856","journal-title":"N Engl J Med"},{"key":"9586_CR23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.1994.12.5.992","volume":"12","author":"B Kristensen","year":"1994","unstructured":"Kristensen B, Ejlertsen B, Dalgaard P et al (1994) Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12:992\u2013997","journal-title":"J Clin Oncol"},{"key":"9586_CR24","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","volume":"42","author":"J Geisler","year":"2006","unstructured":"Geisler J, Lonning PE, Krag LE et al (2006) Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 42:2968\u20132975","journal-title":"Eur J Cancer"},{"key":"9586_CR25","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","volume":"24","author":"EA Perez","year":"2006","unstructured":"Perez EA, Josse RG, Pritchard KI et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17. J Clin Oncol 24:3629\u20133635","journal-title":"J Clin Oncol"},{"key":"9586_CR26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","volume":"369","author":"RC Coombes","year":"2007","unstructured":"Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2\u20133\u00a0years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559\u2013570","journal-title":"Lancet"},{"key":"9586_CR27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8:119\u2013127","journal-title":"Lancet Oncol"},{"key":"9586_CR28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","volume":"21","author":"R Eastell","year":"2006","unstructured":"Eastell R, Hannon RA, Cuzick J et al (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial. J Bone Miner Res 21:1215\u20131223","journal-title":"J Bone Miner Res"},{"key":"9586_CR29","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","volume":"14","author":"I Fogelman","year":"2003","unstructured":"Fogelman I, Blake GM, Blamey R et al (2003) Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2\u00a0years of goserelin or 6\u00a0months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14:1001\u20131006","journal-title":"Osteoporos Int"},{"key":"9586_CR30","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2007.10.7573","volume":"25","author":"KD Crew","year":"2007","unstructured":"Crew KD, Greenlee H, Capodice J et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877\u20133883","journal-title":"J Clin Oncol"},{"key":"9586_CR31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.breast.2008.02.006","volume":"17","author":"C Fontaine","year":"2008","unstructured":"Fontaine C, Meulemans A, Huizing M et al (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast 17:376\u2013381","journal-title":"Breast"},{"key":"9586_CR32","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminoncol.2007.10.005","volume":"34","author":"P Hadji","year":"2007","unstructured":"Hadji P, Bundred N (2007) Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol 34:S4\u2013S10","journal-title":"Semin Oncol"},{"key":"9586_CR33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","volume":"15","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Balena R, Confravreux E et al (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955\u2013962","journal-title":"J Clin Oncol"},{"key":"9586_CR34","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","volume":"14","author":"JE Lester","year":"2008","unstructured":"Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336\u20136342","journal-title":"Clin Cancer Res"},{"key":"9586_CR35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","volume":"12","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631\u2013641","journal-title":"Lancet Oncol"},{"key":"9586_CR36","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM, Harker WG, Beck JT (2012) Final 5-year results of Z-FAST trial. Cancer 118:1192\u20131201","journal-title":"Cancer"},{"key":"9586_CR37","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","volume":"21","author":"H Eidtmann","year":"2010","unstructured":"Eidtmann H, de Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 21:2188\u20132194","journal-title":"Ann Oncol"},{"key":"9586_CR38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","volume":"12","author":"A Llombart","year":"2012","unstructured":"Llombart A, Frassoldati A, Paija O et al (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Canc 12:40\u201348","journal-title":"Clin Breast Canc"},{"key":"9586_CR39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","volume":"117","author":"SL Hines","year":"2009","unstructured":"Hines SL, Mincey B, Dentchev T et al (2009) Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Canc Res Treat 117:603\u2013609","journal-title":"Breast Canc Res Treat"},{"key":"9586_CR40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","volume":"28","author":"C Poznak Van","year":"2010","unstructured":"Van Poznak C, Hannon RA, Mackey JR et al (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967\u2013975","journal-title":"J Clin Oncol"},{"key":"9586_CR41","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"M Gnant","year":"2007","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820\u2013828","journal-title":"J Clin Oncol"},{"key":"9586_CR42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840\u2013849","journal-title":"Lancet Oncol"},{"key":"9586_CR43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679\u2013691","journal-title":"N Engl J Med"},{"key":"9586_CR44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","volume":"118","author":"GK Ellis","year":"2009","unstructured":"Ellis GK, Bone HG, Chlebowski R et al (2009) Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Canc Res Treat 118:81\u201387","journal-title":"Breast Canc Res Treat"},{"key":"9586_CR45","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","volume":"22","author":"P Hadji","year":"2011","unstructured":"Hadji P, Aapro MS, Body JJ et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22:2546\u20132555","journal-title":"Ann Oncol"},{"key":"9586_CR46","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","volume":"8","author":"T Powles","year":"2006","unstructured":"Powles T, Paterson A, McCloskey E et al (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Canc Res 8:R13","journal-title":"Breast Canc Res"},{"key":"9586_CR47","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.ejca.2009.04.022","volume":"45","author":"RE Coleman","year":"2009","unstructured":"Coleman RE (2009) Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 45:1909\u20131915","journal-title":"Eur J Cancer"},{"key":"9586_CR48","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396\u20131405","journal-title":"N Engl J Med"},{"key":"9586_CR49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","volume":"339","author":"IJ Diel","year":"1998","unstructured":"Diel IJ, Solomayer EF, Costa SD et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357\u2013363","journal-title":"N Engl J Med"},{"key":"9586_CR50","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","volume":"102","author":"RE Coleman","year":"2010","unstructured":"Coleman RE, Winter MC, Cameron D et al (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099\u20131105","journal-title":"Br J Cancer"},{"key":"9586_CR51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","volume":"48","author":"T Yan","year":"2012","unstructured":"Yan T, Yin W, Zhou Q et al (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48:187\u2013195","journal-title":"Eur J Cancer"},{"key":"9586_CR52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/0284186X.2011.633555","volume":"51","author":"BL Lee","year":"2012","unstructured":"Lee BL, Higgins MJ, Goss PE (2012) Denosumab and the current status of bone-modifying drugs in breast cancer. Acta Oncol 51:157\u2013167","journal-title":"Acta Oncol"},{"key":"9586_CR53","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(11)70030-4","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, DeCensi A, Arun B et al (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12:496\u2013503","journal-title":"Lancet Oncol"},{"key":"9586_CR54","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","volume":"28","author":"G Rennert","year":"2010","unstructured":"Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577\u20133581","journal-title":"J Clin Oncol"},{"key":"9586_CR55","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","volume":"28","author":"RT Chlebowski","year":"2010","unstructured":"Chlebowski RT, Chen Z, Cauley JA et al (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582\u20133590","journal-title":"J Clin Oncol"},{"key":"9586_CR56","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.biotechadv.2011.06.018","volume":"30","author":"M Marra","year":"2012","unstructured":"Marra M, Salzano G, Leonetti C et al (2012) New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv 30:302\u2013309","journal-title":"Biotechnol Adv"},{"key":"9586_CR57","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijpharm.2010.10.046","volume":"403","author":"G Salzano","year":"2011","unstructured":"Salzano G, Marra M, Porru M et al (2011) Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm 403:292\u2013297","journal-title":"Int J Pharm"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-012-9586-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-012-9586-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-012-9586-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T12:26:32Z","timestamp":1562415992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-012-9586-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,5]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["9586"],"URL":"https:\/\/doi.org\/10.1007\/s12253-012-9586-9","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,5]]}}}